Verastem’s Global Patent Portfolio for COPIKTRA

Jones Day is advising Verastem, Inc (Verastem Oncology).

Jones Day represents Verastem, Inc. (Nasdaq:VSTM) in the establishment of a global patent portfolio related to COPIKTRA® (duvelisib), a small molecule approved for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies.

Verastem Oncology is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer.

The Jones Day team is led by Michael Bruner (Picture).

Involved fees earner: Michael Bruner – Jones Day;

Law Firms: Jones Day;

Clients: Verastem, Inc (Verastem Oncology);

Author: Ambrogio Visconti